La chaîne d'options affiche les données clés des options sur actions de Outlook Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Outlook Therapeutics..

Outlook Therapeutics (NASDAQ:OTLK) Stock, Chaîne d'Options

OUTLOOK THERAPEUTICS INC

Outlook Therapeutics

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics Inc

MBIA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBI#NYSE">MBI</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 69.23 percent increase over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $14.00 million which beat the analyst consensus estimate of $6.00 million by 133.33 percent. This is a 7.69 percent increase over sales of $13.00 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

MBIA Q1 Adj. EPS $(0.16) Misses $(0.13) Estimate, Sales $14.00M Beat $6.00M Estimate

Full Year 2025:&nbsp;&nbsp;
<ul>
<li>Revenue is expected to be in the range of $234.0 – $240.0 million, raising the bottom end of our prior range by $4.0 million.</li>
<li>Adjusted Operating Income is expected to be in the range of $49.0 – $53.0 million.&nbsp;</li>
<li>Adjusted EBITDA is expected to be in the range of $61.0 – $65.0 million, for a full-year adjusted EBITDA margin ranging from 26 – 28%.&nbsp;</li>
<li>Adjusted Net Income is expected to be $30.0 – $34.0 million.&nbsp;</li>
<li>Adjusted Net Income Per Diluted Share is expected to be&nbsp;$0.20 – $0.23 per share on approximately 148.8 million weighted-average shares outstanding.&nbsp; &nbsp;</li>
</ul>

Guidance

Definitive Healthcare Raises FY25 Outlook: Adj EPS From $0.19-$0.22 to $0.20-$0.23 Vs $0.21 Est; Sales From $230.00M-$240.00M To $234.00M-$240.00M Vs $234.28M Est

TTEC Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEC#NASDAQ">TTEC</a>) affirms FY2025 Adj EPS guidance from $0.95-$1.20 to $0.95-$1.20 vs $1.08 analyst estimate. Affirms FY2025 sales outlook from $2.01 billion-$2.06 billion to $2.01 billion-$2.06 billion vs $2.04 billion estimate.

TTEC

TTEC Holdings Affirms FY2025 Adj EPS Guidance of $0.95-$1.20 vs $1.08 Est; Affirms FY2025 Sales Guidance of $2.01B-$2.06B vs $2.04B Est

WIIM

LYFT

Lyft shares are trading higher after the company reported better-than-expected Q1 EPS results. Also, the company announced a $750 million share buyback plan.

Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 78.88 percent increase over losses of $(1.61) per share from the same period last year. The company reported quarterly sales of $381.00 thousand which missed the analyst consensus estimate of $608.25 thousand by 37.36 percent. This is a 30.47 percent decrease over sales of $548.00 thousand the same period last year.

LGVN

Longeveron Q1 EPS $(0.34) Misses $(0.30) Estimate, Sales $381.00K Miss $608.25K Estimate

GrowGeneration (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $35.70 million which missed the analyst consensus estimate of $39.63 million by 9.92 percent. This is a 25.45 percent decrease over sales of $47.89 million the same period last year.

GRWG

GrowGeneration Q1 EPS $(0.16) Misses $(0.14) Estimate, Sales $35.70M Miss $39.63M Estimate

Hub Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBG#NASDAQ">HUBG</a>) lowers FY2025 GAAP EPS guidance from $1.90-$2.40 to $1.75-$2.25 vs $2.12 analyst estimate. Lowers FY2025 sales outlook from $4.00 billion-$4.30 billion to $3.60 billion-$4.00 billion vs $4.05 billion estimate.

HUBG

Hub Group Lowers FY2025 GAAP EPS Guidance from $1.90-$2.40 to $1.75-$2.25 vs $2.12 Est; Lowers FY2025 Sales Guidance from $4.00B-$4.30B to $3.60B-$4.00B vs $4.05B Est

TMDX

TransMedics Group shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance above estimates.

Second Quarter 2025:&nbsp;&nbsp;
<ul>
<li>Revenue is expected to be in the range of $58.5 – $60.0 million.&nbsp;</li>
<li>Adjusted Operating Income is expected to be in the range of $12.0 – $13.0 million.&nbsp;</li>
<li>Adjusted EBITDA is expected to be in the range of $15.0 – $16.0 million, and 25 – 27% adjusted EBITDA margin.&nbsp;</li>
<li>Adjusted Net Income is expected to be $6.5 – $7.5 million.&nbsp;</li>
<li>Adjusted Net Income Per Diluted Share is expected to be&nbsp;$0.04 to $0.05 per share on approximately 147.9 million weighted-average shares outstanding.&nbsp;</li>
</ul>

Definitive Healthcare Sees Q2 Adj EPS $0.04-$0.05 vs $0.05 Est; Sees Sales $58.500M-$60.000M vs $58.29M Est

TTEC Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEC#NASDAQ">TTEC</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.22 by 27.27 percent. This is a 3.7 percent increase over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $534.23 million which beat the analyst consensus estimate of $513.08 million by 4.12 percent. This is a 7.35 percent decrease over sales of $576.64 million the same period last year.

TTEC Holdings Q1 Adj. EPS $0.28 Beats $0.22 Estimate, Sales $534.23M Beat $513.08M Estimate

CRVS

Corvus Pharmaceuticals shares are trading higher after it reported Q1 EPS. Company also reported data from its Cohorts 1-3 of Placebo-Controlled phase 1 clinical trial

Sensata Technologies Holdings shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 guidance above estimates.

When <a href="https://www.benzinga.com/personal-finance/25/04/45059919/elon-musk-said-with-confidence-i-know-more-about-manufacturing-than-anyone-alive-then-the-cybert">people think of Tesla</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), they think Elon Musk. Fast cars, space-age tech, memes about "funding secured"—it all screams Musk. But here's a shocker: Musk didn't even name the company. In fact, he wasn't the founder either.
That's right. Musk joined Tesla in 2004, a year after it was founded by engineers Martin Eberhard and Marc Tarpenning. Yet somehow, over time, the public started thinking Musk not only built the first Roadster in his garage but also coined the name Tesla. Both are myths.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
In a 2018 interview with Lesley Stahl on <a href="https://youtu.be/-0gy0p9jnN0?si=9R2a4EZx_xf6y9W9">CBS's "60 Minutes"</a>, Musk set the record straight.
He first clarified that he pronounces Tesla with a "slight z sound," not an "s." Then, as the segment continued, he explained:
"We didn't actually come up with the name Tesla Motors. We didn't own the name. It was a guy in Sacramento who came up with the name and owned the name, and we had to buy it off him for $75,000."
But the story gets even better. The Sacramento man wasn't exactly eager to part with the name. So, Musk pulled a move straight out of a sitcom.
"I sent the nicest guy in the company to just go sit on his doorstep and not leave until he agreed to sell it to us," Musk recalled. "A sweet guy, but nicest impossible to anger… so officially just the guy said fine, I'll sell you the name if you leave my doorstep. Yeah, pretty much."
That's how Tesla Motors became Tesla Motors.
Trending: Donald Trump just announced a $500 billion AI infrastructure deal — <a href="https://www.benzinga.com/money/seize-a-share-while-you-still-can-in-the-2-trillion-entertainment-market-with-elf-labs-at-just-2-25-share">here's how you can invest in the entertainment market's next big disruptor at $2.25 per share</a>.
If the $75,000 name deal had fallen through, Musk had a backup plan. The top alternative? Faraday.
The name was a nod to Michael Faraday, the 19th-century British scientist whose pioneering work in electromagnetism made modern electric motors and generators possible — technology at the heart of Tesla's mission. It turned out to be a good name to leave on the table. <a href="https://www.benzinga.com/25/04/45081620/faraday-future-ffai-shares-surge-50-amid-leadership-changes-and-strategic-updates">Faraday Future</a>, a rival EV startup, eventually scooped it up.
Now, the founder mix-up isn't entirely random. Musk led Tesla's first major funding round, throwing in $6.5 million of his own money and becoming chairman. Over time, he became the company's frontman, visionary, and eventually <a href="https://www.benzinga.com/markets/equities/25/05/45126370/elon-musk-will-remain-tesla-ceo-for-at-least-5-years-says-dan-ives-as-company-calls-replacement-rumors-absolutely-false">CEO in 2008</a>. After a legal settlement with Eberhard, Musk and a few others were <a href="https://m.economictimes.com/magazines/panache/was-elon-musk-really-a-tesla-co-founder-how-he-became-synonymous-with-the-brand/articleshow/119340540.cms">officially recognized as "co-founders,"</a> but that was years after the company's birth.
So no, he didn't invent the tech or pick the name—but he did bet big and drive Tesla to global dominance.
Elon Musk may not have founded Tesla or named it, but he sure made it famous. And he was willing to pay—and negotiate creatively—to get the name that would eventually become a household brand.
Read Next:
<ul>
<li>Shark Tank's Kevin O'Leary called Missing Ring his biggest mistake — Don't repeat history—<a href="https://www.benzinga.com/money/big-tech-has-spent-billions-acquiring-ai-smart-home-startups-one-company-stands-to-benefit-and-has-already-made-10-million">invest in RYSE at just $1.90/share.</a></li>
<li><a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market">Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold.</a></li>
</ul>
Image: Shutterstock

Personal Finance

TSLA

Elon Musk Says 'We Didn't Come Up With The Name Tesla'—Bought It For $75K After Sending 'The Nicest Guy' To Camp Out At The Owner's Doorstep

Definitive Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 37.5 percent decrease over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $59.19 million which beat the analyst consensus estimate of $56.18 million by 5.35 percent. This is a 6.76 percent decrease over sales of $63.48 million the same period last year.

Definitive Healthcare Q1 Adj. EPS $0.05 Beats $0.02 Estimate, Sales $59.19M Beat $56.18M Estimate

Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.01 by 400 percent. This is a 16.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $13.08 million which beat the analyst consensus estimate of $13.02 million by 0.44 percent. This is a 56.00 percent decrease over sales of $29.72 million the same period last year.

JYNT

Joint Q1 EPS $0.05 Beats $0.01 Estimate, Sales $13.08M Beat $13.02M Estimate

Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) released its third-quarter results after Thursday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/25/05/b45299243/affirm-reports-third-fiscal-quarter-2025-results">figures in the report. </a>
The Details: Affirm reported quarterly losses of one cent per share, which beat the Street estimate of losses of three cents. Quarterly revenue of $783.13 million beat the consensus estimate of $783.03 million and is up from revenue of $576.16 million from the prior year&#8217;s quarter.
Read Next: <a href="https://www.benzinga.com/news/earnings/25/05/45292652/thursdays-top-5-trending-stocks-whats-going-on-with-d-wave-novavax-carvana?utm_source=articleShare">Thursday&#8217;s Top 5 Trending Stocks: What&#8217;s Going On With D-Wave, Novavax, Carvana?</a>
For the third quarter, Affirm reported:
<ul>
<li>Gross Merchandise Volume (GMV) grew 36% to $8.6 billion. </li>
<li>Direct-to-Consumer GMV (D2C GMV) grew 50% to $2.4 billion and Affirm Card GMV within this grew 115% to $807 million. </li>
<li>Active consumers, excluding the discontinued Returnly business, increased 23% to 21.9 million. </li>
<li>Active merchant count increased 23% to 358,000 at the end of the quarter. </li>
</ul>
&#8220;Demand for Affirm remains excellent: year-over-year GMV growth accelerated for the third consecutive quarter, including a strong March, which continued into April. Credit outcomes are in line with our predictions, and as always, we are watching attentively for any indicators of macroeconomic stress, and fine-tuning the settings of our models continuously, CEO Max Levchin wrote in a letter to shareholders.
AFRM Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Affirm stock was down 7.96% at $49.94 after-hours Thursday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/travel/25/05/45260938/disneys-new-abu-dhabi-theme-park-will-be-authentically-disney-and-distinctly-emirati-ceo-bob-iger-says?utm_source=articleShare">Disney&#8217;s New Abu Dhabi Theme Park Will Be &#8216;Authentically Disney And Distinctly Emirati,&#8217; CEO Bob Iger Says&nbsp;</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

After-Hours Center

Movers

AFRM

Affirm Stock Sinks Despite Better-Than-Expected Q3 Results

Hub Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBG#NASDAQ">HUBG</a>) reported quarterly earnings of $0.44 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $915.22 million which missed the analyst consensus estimate of $966.16 million by 5.27 percent. This is a 8.43 percent decrease over sales of $999.49 million the same period last year.

Hub Group Q1 EPS $0.44, Inline, Sales $915.22M Miss $966.16M Estimate

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.16) by 50 percent. This is a 26.32 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $10.46 million which missed the analyst consensus estimate of $15.36 million by 31.89 percent. This is a 51.66 percent decrease over sales of $21.64 million the same period last year.

NKTR

Nektar Therapeutics Q1 EPS $(0.24) Misses $(0.16) Estimate, Sales $10.46M Miss $15.36M Estimate

BLND

Blend Sees Q2 Blend Platform Revenue $30.5M–$32.5M

PubMatic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PUBM#NASDAQ">PUBM</a>) sees Q2 sales of $66.000 million-$70.000 million vs $67.42 million analyst estimate.

PUBM

PubMatic Sees Q2 Sales $66.000M-$70.000M vs $67.42M Est

Press Releases

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Comments

Outlook Therapeutics

Outlook Therapeutics (OTLK) Options

Outlook Therapeutics (NASDAQ:OTLK) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL